FILSPARI sales surge meets new supply and regulatory hurdles
- FILSPARI is approved for IgAN and FSGS, giving Travere one main drug with two rare kidney disease markets.
- Management sees more than 100,000 eligible U.S. patients and a $3 billion peak sales chance for FILSPARI.
- Q2 2026 FILSPARI net sales reached $141.1 million, proving strong launch demand.
- The company added a new oral drug candidate called civorebrutinib in June 2026 to rebuild its pipeline.
- New risks emerged recently with an FDA marketing warning and a key supplier facing BIOSECURE Act limits.
One drug, bigger target, new obstacles
Travere remains a FILSPARI execution story. The drug sells for IgA nephropathy, or IgAN, a kidney disease that can lead to kidney failure. In April 2026, the FDA also approved FILSPARI for focal segmental glomerulosclerosis, or FSGS. That turned one product into a two-market launch, and Q2 2026 sales hit $141.1 million as demand continued to grow.
The bull case relies on that momentum. Management says more than 100,000 U.S. patients could be eligible across both conditions and sees a $3 billion peak sales chance. Travere also expanded its pipeline by licensing civorebrutinib, an oral BTK inhibitor, giving the company another future growth pillar.
The bear case centers on execution barriers. Travere set a high bar by saying FSGS should ramp faster than IgAN. Meanwhile, new complications have surfaced. The primary supplier for the active ingredient in FILSPARI was added to a restricted list under the BIOSECURE Act, which means the company must quickly find alternative sources. Additionally, the FDA issued a warning letter regarding FILSPARI marketing materials.
The next test is how management handles these hurdles. Investors will be watching whether the supply chain shift causes delays and whether the marketing warning slows down the strong launch trajectory.
Selling rare disease drugs
Travere makes money mostly by selling approved drugs in the U.S. Its main product is FILSPARI. It also sells Thiola and Thiola EC for cystinuria, a rare disorder that causes kidney stones, though those older drugs face generic competition.
Outside the U.S., Travere licenses sparsentan rights to CSL Vifor and Chugai. Those deals can bring in milestones and royalties, which are high-value revenue streams if partner sales grow.
The model works best when a rare disease drug has strong patent protection, clear payer coverage, and a reliable supply chain. It breaks if launch uptake is slower than expected, if insurers push back, or if reliance on third-party manufacturers causes supply disruptions.
What Travere sells and studies
FILSPARI for IgAN
FILSPARI is approved to slow kidney function decline in adults with IgAN at risk of progression. It is the base of Travere's current growth, helping drive $141.1 million in Q2 2026 sales.
FILSPARI for FSGS
The FDA granted full approval on April 13, 2026, for certain FSGS patients aged 8 years and older. Management expects uptake to be faster than the IgAN launch.
Thiola and Thiola EC
These tiopronin products treat cystinuria. They produced $20.3 million of Q2 2026 net product revenue, but several approved generics make this a shrinking profit support over time.
Civorebrutinib
Licensed from Everest Medicines in June 2026, this oral BTK inhibitor is targeted for rare immune-mediated kidney diseases.
Pegtibatinase
Pegtibatinase is in the Phase 3 HARMONY study for classical homocystinuria, a rare metabolic disease. Topline data is expected in the second half of 2027.
Q2 revenue mix
Travere reports as one operating segment, so this mix uses Q2 2026 revenue by product and type. FILSPARI was about 83 percent of total Q2 revenue, showing how concentrated the story has become.
What could break the story
Supply chain disruptions
High impact · Medium oddsThe primary supplier for the active ingredient in FILSPARI was added to a restricted list under the BIOSECURE Act. Travere must qualify alternative sources quickly to avoid supply shortages or higher costs.
Marketing claims pullback
Medium impact · Medium oddsThe FDA issued an untitled letter in July 2026 over FILSPARI marketing materials. This could slow launch momentum if the company has to pull back its sales messaging or retrain its sales force.
FSGS launch misses the fast-ramp claim
High impact · Medium oddsManagement has said FSGS uptake should be faster than the IgAN launch. That may not happen if doctors pause over the label language or if the real treated population is smaller than expected.
Thiola fades faster than planned
Medium impact · High oddsThiola and Thiola EC still matter because they help fund the company. Several generic versions are approved, so sales could erode faster and leave a gap before FILSPARI fully offsets it.
Pegtibatinase stumbles again
Medium impact · Medium oddsThe HARMONY study has restarted, but it had been paused because of manufacturing scale-up issues. If those problems return, Travere loses a key pipeline option.
In one breath
What does Travere Therapeutics do?
Travere develops and sells drugs for rare kidney and metabolic diseases. Its main product is FILSPARI, which is approved for IgAN and certain FSGS patients.
Why does FILSPARI matter so much to TVTX stock?
FILSPARI is the main growth engine. Management sees a $3 billion peak sales chance across IgAN and FSGS, so the stock depends heavily on whether that launch keeps growing.
What is the BIOSECURE Act risk for Travere?
The primary supplier for FILSPARI's active ingredient was placed on a restricted list under the BIOSECURE Act. Travere is now working to find and qualify new suppliers to avoid drug shortages.
What is the biggest near-term catalyst for Travere?
The next big readouts are launch data. Q3 and Q4 2026 results should give the first real numbers on whether FSGS is adding meaningful growth, while investors watch for updates on the supply chain.
